The Karolinska Portfolio Company Development Anacardio includes the first patient in a study in phase 2A of his candidate for drugs AC01

Stockholm, Sweden, February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Anacardio has dosed the first patient in phase of HOP-HF1. The study will evaluate the candidate for the Anacardio AC01 drug in patients with heart failure and reduced ejection fraction. The results of the study from Gow-HF1 are expected by the end of the year.

Anacardio AB is a biopharmaceutical company at a clinical stage in a privately owned clinical stage that develops new drugs to treat heart failure. The main assets of the company, AC01, is currently evaluated in a 1B/2A phase, POW-HF1, in patients with heart failure and reduced ejection fraction (HFREF).

The 2A phase part of the Gow-HF1 study is randomized, double-blind and placentbo controlled, which aims to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in patients with HFREF after 28 days of treatment. The study is conducted in 13 centers of highly specialized heart failure in Sweden, Holland, Italy and the United Kingdom.

“Following the promising results in the first part of the 1B/2A phase study, we are pleased to see our Anacardio portfolio that advances the clinical development of AC01 by initiating the second part of the study,” says Viktor Drvota, CEO, Karolinska Development Development, Karolinska Development, Karolinska Development.

The interest of the Development of Karolinska for Anacardio amounts to 10%.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: [email protected]

Johan Dighed, General Counselor and Deputy General Manager, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: [email protected]

To publishers

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a northern life science investment company. The company focuses on identifying advanced medical innovations in the northern region that are developed by entrepreneurs and management teams. The company invests in the creation and growth of companies that advance these assets in commercial products that are designed to make the difference in patients’ lives, while offering an attractive yield of shareholders.

Karolinska Development has access to world -class medical innovations at Karolinska Institutet and other leading universities and research institutes in the northern region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced teams and advisers co-financed by specialized international investors, to provide the highest chances of success.

Karolinska Development has a portfolio of eleven companies that aim for opportunities in innovative treatment for diseases that can endanger or serious debilitating.

The company is run by an entrepreneurial team of investment professionals, with a historian proven as companies and with access to a strong global network.

For more information please visit www.karolinskadevelopment.com.